PD470 - PREVALENCE OF SARCOPENIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PILOT CROSS-SECTIONAL STUDY

PD470

PREVALENCE OF SARCOPENIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PILOT CROSS-SECTIONAL STUDY

A. Kaliyakparova^1,*, J. Kaibullayeva¹, A. Mukhamejan¹, A. Almas¹

¹Scientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan

Rationale: Aim. To assess the prevalence of presarcopenia, sarcopenia, and severe sarcopenia in patients with inflammatory bowel disease (IBD) and to explore their association with disease activity and biologic therapy.

Methods: This pilot cross-sectional study included 46 patients with IBD (23 men and 23 women; mean age 41.5±14.8 years), including 23 with Crohn’s disease and 23 with ulcerative colitis. Muscle status was evaluated using the Short Physical Performance Battery (SPPB), muscle mass assessment, and handgrip dynamometry. Patients were classified as normal, presarcopenic, sarcopenic, or severely sarcopenic according to the combination of reduced muscle mass, muscle strength, and physical performance. Disease activity, clinical phenotype, and biologic therapy use were recorded.

Results: Reduced muscle mass was found in 73.9% of patients, reduced handgrip strength in 45.7%, and impaired physical performance in 28.3%. Normal muscle status was observed in 26.1% of patients, presarcopenia in 28.3%, sarcopenia in 17.4%, and severe sarcopenia in 28.3%. Overall, any sarcopenic disorder was present in 73.9% of the cohort. Its prevalence was higher in Crohn’s disease than in ulcerative colitis (78.3% vs 69.6%). Patients with moderate-to-high disease activity more often had sarcopenic disorders than those in remission or with minimal/inactive disease (93.8% vs 63.3%), and severe sarcopenia was also more frequent in this group (62.5% vs 10.0%). Reduced handgrip strength was less common in patients receiving biologic therapy than in those not receiving biologics (26.3% vs 59.3%)

Conclusion: Sarcopenia and its early stages are highly prevalent in patients with IBD. Greater inflammatory activity appears to be associated with more severe muscle impairment, while biologic therapy may be linked to better preservation of muscle strength. Larger prospective studies are needed to confirm these findings

Disclosure of Interest: None declared